[go: up one dir, main page]

WO2003048204A1 - Alzheimer’s disease-associated gene and protein and use thereof - Google Patents

Alzheimer’s disease-associated gene and protein and use thereof Download PDF

Info

Publication number
WO2003048204A1
WO2003048204A1 PCT/JP2002/012749 JP0212749W WO03048204A1 WO 2003048204 A1 WO2003048204 A1 WO 2003048204A1 JP 0212749 W JP0212749 W JP 0212749W WO 03048204 A1 WO03048204 A1 WO 03048204A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
disease
alzheimer
associated gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/012749
Other languages
French (fr)
Japanese (ja)
Inventor
Hiroto Komano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL
National Institute of Advanced Industrial Science and Technology AIST
Takeda Pharmaceutical Co Ltd
Original Assignee
JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL
Agency of Industrial Science and Technology
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL, Agency of Industrial Science and Technology, Takeda Chemical Industries Ltd filed Critical JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL
Priority to AU2002354433A priority Critical patent/AU2002354433A1/en
Publication of WO2003048204A1 publication Critical patent/WO2003048204A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

It is intended to provide a gene regulating the production of amyloid β protein, a protein and use thereof. More specifically speaking, a gene regulating the production of amyloid β protein, a protein encoded by the gene or its salt, an antibody against the protein, a diagnostic or a drug containing the antibody, a method of screening a compound which is efficacious in treating Alzheimer’s disease with the use of the protein, etc. are provided.
PCT/JP2002/012749 2001-12-06 2002-12-05 Alzheimer’s disease-associated gene and protein and use thereof Ceased WO2003048204A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002354433A AU2002354433A1 (en) 2001-12-06 2002-12-05 Alzheimer's disease-associated gene and protein and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-373050 2001-12-06
JP2001373050 2001-12-06

Publications (1)

Publication Number Publication Date
WO2003048204A1 true WO2003048204A1 (en) 2003-06-12

Family

ID=19181834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012749 Ceased WO2003048204A1 (en) 2001-12-06 2002-12-05 Alzheimer’s disease-associated gene and protein and use thereof

Country Status (2)

Country Link
AU (1) AU2002354433A1 (en)
WO (1) WO2003048204A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058356A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058356A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 human secreted proteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] KOMANO H. ET AL.: "A new functional screening system identified cDNA which increase gamma-cleavage", XP002965865, accession no. DIALOG Database accession no. 200100482637 *
DATABASE BIOSIS [online] SAI X. ET AL.: "ER stress- induced membrane-associated protein increases gamma-cleavage", XP002965866, accession no. DIALOG Database accession no. 200100552012 *
KOMANO H. ET AL.: "A new functional screening system for identification of regulators for the generation of amyloid beta-protein", J. BIOL. CHEM., vol. 277, no. 42, October 2002 (2002-10-01), pages 39627 - 39633, XP002965868 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, November 2001 (2001-11-01), pages 1439 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, November 2001 (2001-11-01), pages 512 *
SUDOH S. ET AL.: "Intracellular site of gamma-secretase cleavage for Abeta42 generation in neuro 2a cells harbouring a presenilin 1 mutation", EUR. J. BIOCHEM., vol. 267, no. 7, April 2000 (2000-04-01), pages 2036 - 2045, XP002951097 *
TOUCHOT N. ET AL.: "Biochemical properties of the YPT-related rab1B protein comparison with rab1A", FEBS LETT., vol. 256, no. 1-2, 1989, pages 79 - 84, XP002965867 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
AU2002354433A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
WO2003014162A1 (en) ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
EP2465872A3 (en) Anti-ADDL antibodies and uses thereof
EP1765388B8 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
EP2305286A3 (en) Treatment for Alzeimer's disease
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
WO2003028631A3 (en) Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
WO2003001983A3 (en) Methods for diagnosing and treating a disease mediated by decreased mmp-2 function
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003048204A1 (en) Alzheimer’s disease-associated gene and protein and use thereof
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
WO2005006949A3 (en) Methods for predicting development of auto-immune diseases and treatment of same
CA2534643A1 (en) Methods for screening and identifying compounds
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
WO2003012141A1 (en) Method of screening alzheimer’s disease-associated gene
WO2007067512A3 (en) Method for identifying modulators of adprh useful for treating alzheimer's disease
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2005002573A3 (en) Methods for using modulators of proline-rich tyrosine kinase 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP